320 related articles for article (PubMed ID: 30082325)
1. Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial.
Zhou JJ; Schwenke DC; Bahn G; Reaven P;
Diabetes Care; 2018 Oct; 41(10):2187-2194. PubMed ID: 30082325
[TBL] [Abstract][Full Text] [Related]
2. Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.
Zhou JJ; Koska J; Bahn G; Reaven P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1150-1162. PubMed ID: 33367811
[TBL] [Abstract][Full Text] [Related]
3. Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT).
Koska J; Nuyujukian DS; Bahn GD; Zhou JJ; Reaven PD
Cardiovasc Diabetol; 2021 Dec; 20(1):232. PubMed ID: 34879878
[TBL] [Abstract][Full Text] [Related]
4. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
Abraira C; Duckworth W; McCarren M; Emanuele N; Arca D; Reda D; Henderson W;
J Diabetes Complications; 2003; 17(6):314-22. PubMed ID: 14583175
[TBL] [Abstract][Full Text] [Related]
5. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial.
Davis SN; Duckworth W; Emanuele N; Hayward RA; Wiitala WL; Thottapurathu L; Reda DJ; Reaven PD;
Diabetes Care; 2019 Jan; 42(1):157-163. PubMed ID: 30455335
[TBL] [Abstract][Full Text] [Related]
6. Glycaemic variation is a predictor of all-cause mortality in the Veteran Affairs Diabetes Trial.
Zhou JJ; Koska J; Bahn G; Reaven P
Diab Vasc Dis Res; 2019 Mar; 16(2):178-185. PubMed ID: 31014099
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Long-term HbA
Sheng CS; Tian J; Miao Y; Cheng Y; Yang Y; Reaven PD; Bloomgarden ZT; Ning G
Diabetes Care; 2020 Jun; 43(6):1185-1190. PubMed ID: 32229597
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study.
Scott ES; Januszewski AS; O'Connell R; Fulcher G; Scott R; Kesaniemi A; Wu L; Colagiuri S; Keech A; Jenkins AJ
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32766757
[TBL] [Abstract][Full Text] [Related]
9. Association of visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with type 2 diabetes: A subanalysis of the EMPATHY trial.
Sato M; Inaishi J; Saisho Y; Sato Y; Komuro I; Itoh H
J Diabetes Investig; 2021 Dec; 12(12):2190-2196. PubMed ID: 34013644
[TBL] [Abstract][Full Text] [Related]
10. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.
Saremi A; Schwenke DC; Bahn G; Ge L; Emanuele N; Reaven PD;
Metabolism; 2015 Feb; 64(2):218-25. PubMed ID: 25456099
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes.
Sun B; He F; Gao Y; Zhou J; Sun L; Liu R; Xu H; Chen X; Zhou H; Liu Z; Zhang W
Endocrine; 2019 Jun; 64(3):536-543. PubMed ID: 30868413
[TBL] [Abstract][Full Text] [Related]
12. Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c.
Tang X; Li S; Wang Y; Wang M; Yin Q; Mu P; Lin S; Qian X; Ye X; Chen Y
Clin Chim Acta; 2016 Oct; 461():146-50. PubMed ID: 27502250
[TBL] [Abstract][Full Text] [Related]
13. Visit-to-Visit Variations in Fasting Plasma Glucose and HbA
Li TC; Yang CP; Tseng ST; Li CI; Liu CS; Lin WY; Hwang KL; Yang SY; Chiang JH; Lin CC
Diabetes Care; 2017 Sep; 40(9):1210-1217. PubMed ID: 28705834
[TBL] [Abstract][Full Text] [Related]
14. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
15. Glycemic Markers and Subclinical Cardiovascular Disease: The Jackson Heart Study.
Echouffo-Tcheugui JB; Chen H; Kalyani RR; Sims M; Simpson S; Effoe VS; Correa A; Bertoni AG; Golden SH
Circ Cardiovasc Imaging; 2019 Mar; 12(3):e008641. PubMed ID: 30879330
[TBL] [Abstract][Full Text] [Related]
16. Visit-to-visit glycemic variability is a strong predictor of chronic obstructive pulmonary disease in patients with type 2 diabetes mellitus: Competing risk analysis using a national cohort from the Taiwan diabetes study.
Chiu HT; Li TC; Li CI; Liu CS; Lin WY; Lin CC
PLoS One; 2017; 12(5):e0177184. PubMed ID: 28489885
[TBL] [Abstract][Full Text] [Related]
17. Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular events.
Sheng L; Yang G; Chai X; Zhou Y; Sun X; Xing Z
Front Endocrinol (Lausanne); 2024; 15():1323571. PubMed ID: 38419951
[TBL] [Abstract][Full Text] [Related]
18. HbA
Metcalf PA; Kyle C; Kenealy T; Jackson RT
J Diabetes Complications; 2017 May; 31(5):814-823. PubMed ID: 28319002
[TBL] [Abstract][Full Text] [Related]
19. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes.
Duckworth WC; McCarren M; Abraira C;
Endocr Pract; 2006; 12 Suppl 1():85-8. PubMed ID: 16627388
[TBL] [Abstract][Full Text] [Related]
20. Influence of Fasting Plasma Glucose Targets on Glycemic Variability in Chinese Participants With Type 2 Diabetes: A Post Hoc Analysis of the FPG GOAL Trial (BEYOND III).
Li L; Yang T; Xue Y; Ruan P; Du J; Li Y; Zhang X; Cui N; Yang W
Adv Ther; 2022 Jan; 39(1):421-429. PubMed ID: 34757600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
